Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NKGen Biotech ( (NKGN) ) has shared an announcement.
NKGen Biotech, Inc. has been approved by the Seoul Bankruptcy Court as the final preferred bidder for acquiring a majority interest in NKMAX Co., Ltd., following stakeholder approval on June 18, 2025. The acquisition, expected to be completed in early August 2025, marks a significant step for NKGen Biotech in expanding its operations and influence in the biotechnology sector, potentially impacting its market positioning and stakeholder interests.
More about NKGen Biotech
NKMAX Co., Ltd., founded in 2002 and headquartered in Seoul, South Korea, is a clinical-stage biotechnology company focused on advancing immune cell therapies. It develops and commercializes bioreagents, immunodiagnostic kits, and health supplements, and operates a GMP-certified manufacturing facility for high-quality cell therapy production. NKMAX is listed on the KOSDAQ stock exchange, though trading has been suspended due to ongoing rehabilitation efforts.
Average Trading Volume: 180,452
Technical Sentiment Signal: Sell
Current Market Cap: $10.79M
Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page.